Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis

Click to increase image sizeClick to decrease image size

Author contributions

Stefano Molica and Diana Giannarelli designed the study and interpreted the data. Diana Giannarelli was responsible for statistical analysis. Stefano Molica wrote the paper and interpreted the data. All authors approved the manuscript.

Disclosure statement

SM received honoraria from Janssen, Abbvie, and AstraZeneca and advisory boards for Janssen, Abbvie, and AstraZeneca. DG nothing to declare. No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.